Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AbbVie is currently conducting a Phase 3 clinical study titled A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis. The study aims to evaluate the safety and efficacy of oral upadacitinib compared to subcutaneous dupilumab in treating moderate to severe atopic dermatitis in children who require systemic therapy.
The study tests two interventions: upadacitinib, an oral tablet or solution, and dupilumab, a subcutaneous injection. Upadacitinib is already approved for patients aged 12 and older, and this study seeks to expand its use to younger children.
This interventional study is randomized with a parallel assignment model and single masking for outcome assessors. The primary purpose is treatment, focusing on assessing adverse events and changes in disease activity.
The study began on August 19, 2024, with a primary completion date yet to be announced. The latest update was submitted on August 5, 2025. These dates are crucial for tracking the study’s progress and potential market impacts.
The study’s outcome could significantly influence AbbVie’s stock performance and investor sentiment, especially if upadacitinib proves effective in younger patients. This could position AbbVie favorably against competitors in the pediatric dermatology market.
The study is ongoing, with further details available on the ClinicalTrials portal.